NexGel, Inc Common Stock
NXGLNexGel, Inc. is a biotechnology company specializing in developing proprietary hydrogel-based delivery systems for wound care and tissue regeneration applications. The company's innovative platforms aim to improve healing processes and enhance patient outcomes through advanced biomedical solutions.
Company News
NEXGEL has created a spin-off company, NexGelRx, to focus exclusively on developing prescription drug delivery solutions using its proprietary hydrogel technology. NEXGEL will retain a 19.99% non-dilutive equity stake and receive a 5% perpetual global royalty.
NEXGEL reported stable Q3 2025 revenue of $2.9 million, improved gross profit margins, and narrowed adjusted EBITDA losses. The company signed new partnerships, launched product lines, and received non-dilutive financing from Stada, positioning for potential growth in Q4.
NEXGEL, Inc. announced it will report its financial results for the first quarter of 2025 on May 13, 2025. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results.
NEXGEL, Inc. announced a $2 million registered direct offering, issuing 727,272 shares of common stock and warrants to purchase 363,636 shares. The proceeds will be used to increase inventory, marketing, and support growth.
NEXGEL, Inc. announced the appointment of Kip Crecca to its Scientific Advisory Board, citing his wealth of knowledge and experience in the medical device sales industry. Crecca will collaborate with NEXGEL's team to support the development of new therapies using the company's hydrogel products.
